This article is more than 5 years old. Information may no longer be current.
Micropulse transscleral cyclophotocoagulation reduces IOP in advanced primary open angle glaucoma
Click Here to Manage Email Alerts
LOS ANGELES — Micropulse transscleral diode laser cyclophotocoagulation is a safe and promising IOP-lowering treatment for patients with advanced primary open angle glaucoma, according to a speaker at the American Society of Cataract and Refractive Surgery meeting.
To demonstrate safety and clinical efficacy of this method, Thomas John, MD, and colleagues conducted a retrospective review of 49 eyes of 35 patients with unilateral and bilateral advanced POAG.
Thomas John
Twenty-nine eyes received a single treatment while six eyes received repeated treatment with micropulse transscleral cyclophotocoagulation. The Cyclo G6 laser system (Iridex) with MicroPulse P3 probe was used for the procedure, delivering 2,000 mW of diode laser energy over 80 seconds to perform two arcs in each eye.
Changes in IOP and number of medications as well as postoperative complications were evaluated.
“Mean IOP was reduced from 24.1 mm Hg to 15.8 mm Hg. The cup-to-disc ratio remained stable with an average of 0.89, ranging between 0.9 and 1.0,” John said, pointing out that the majority of patients in the group had advanced nerve cupping.
The number of medications was reduced from 3.1 to 2.9. Postoperative inflammation was minimal and no complications were reported, including hypotony, which is a well-known effect of continuous-wave cyclophotocoagulation. – by Michela Cimberle
Reference:
John T. Micropulse transscleral diode laser cyclophotocoagulation in primary advanced open angle glaucoma. Presented at: American Society of Cataract and Refractive Surgery annual meeting; May 5-9, 2017; Los Angeles.
Disclosure: John reports he is a consultant for Bausch + Lomb.